2017: Probiodrug loss-making biotech, not a stock for the Defensive Investor
2018: stock price has dropped from EUR 17 to EUR 3,20
Book value per share? Equity has dropped from EUR 9m to 5m in the first half of the year. Could go to zero in the second half of 2018?
Do you speak Dutch? If so please opt-in at www.valuemachinesfund.nl Thanks in advance! Comments, questions or E-mails welcome: email@example.com